glp-1 drugs differences medications GLP-1 Drug Overdose difference in glp 1 medications

greater reductions occur in patients with higher baseline HbA1c values

AstraZeneca has agreed to pay CSPC $1.2 billion up front and up to $3.5 billion in development and regulatory milestone payments across eight drug development programs for weight loss and Type 2 diabetes, the British firm says in a Jan

Dankner R, Roth J

Medicare Obesity Coverage Expansion (Regulatory): The Centers for Medicare & Medicaid Services (CMS) announced that beginning in April 2026, Medicare will cover GLP-1 medications for beneficiaries with obesity and qualifying comorbidities via the BALANCE Model and Section 402 demonstrations, marking a reversal of the long-standing statutory ban on weight-loss drug coverage

For health authorities, the report signals the need to monitor compounded GLP-1 RAs with sharper attention to licensing status and enforcement history